Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours ner response:	0.5							

					or :	Section	on 30(n) d	or the	Investment C	ompany Ac	t of 1940						
Name and Address of Reporting Person*  Mehro Appard				2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ ACRS ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Mehra Anand								-1-	,		-		X Directo	or		10% Ow	/ner
	LARIS THE	ERAPEUTICS, 1	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2021							Officer (give title below)			Other (s below)	pecify	
640 LEE ROAD, SUITE 200				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. lı	6. Individual or Joint/Group Filing (Check Applicable						
(Street)												Line)  X Form filed by One Reporting Person					
WAYNE	PA	A	19087									Form f Persor	orm filed by More than One Reporting				
(City)	(S	tate)	(Zip)														
		Tab	le I - Non-	Deriva	ative	Se	curities	s Ac	quired, Di	sposed	of, or Be	neficial	ly Owned	I			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			Execution Date		Code (Instr. 5)				Beneficia	es Form ally (D) o Following (I) (Ir		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code V	Amoun	(A) o	r Price	Transact (Instr. 3	tion(s)			(111311. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	titve Conversion Date Execution Date, ity or Exercise (Month/Day/Year) if any		ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				c	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$21.9	06/03/2021			A		12,250		(1)(2)	06/02/2031	Common Stock	12,250	\$0.00	12,250	)	D	

(1)(4)

## **Explanation of Responses:**

- 1. This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy.
- 2. The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date.

3.356

- 3. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 4. The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date.

## Remarks:

Restricted

/s/ Mark Ballantyne, Attorney-

3,356

\$0.00

06/04/2021

3.356

D

Common

Stock

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/03/2021

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.